Share Price and Basic Stock Data
Last Updated: November 6, 2025, 8:17 pm
| PEG Ratio | 5.08 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Bal Pharma Ltd operates in the pharmaceuticals industry, focusing on the development and manufacturing of various pharmaceutical products. As of the latest data, the company recorded a market capitalization of ₹131 Cr and a share price of ₹82.5. The revenue from operations for the financial year ending March 2025 stood at ₹303 Cr, a slight decline from ₹339 Cr in March 2024. Quarterly sales trends indicate fluctuations, with the highest sales of ₹94.63 Cr recorded in March 2024, followed by a decrease to ₹65.87 Cr in June 2025. This inconsistency in revenue generation highlights the company’s vulnerability to market dynamics. Sales from March 2023 to March 2025 showed a growth trajectory, with reported sales increasing from ₹304 Cr to ₹303 Cr, reflecting operational challenges in sustaining growth. With a trailing twelve-month (TTM) revenue of ₹295 Cr, Bal Pharma faces competitive pressures typical in the pharmaceutical sector, where innovation and cost efficiency are critical.
Profitability and Efficiency Metrics
Bal Pharma’s profitability metrics present a mixed picture. The company reported an operating profit margin (OPM) of 9.20%, which is relatively low compared to industry averages, indicating potential inefficiencies in cost management. The net profit for the financial year ending March 2025 was ₹7 Cr, leading to an earnings per share (EPS) of ₹4.54. The return on equity (ROE) stood at 9.66%, while the return on capital employed (ROCE) was reported at 10.1%, suggesting that the company is generating reasonable returns on its equity and capital. However, the interest coverage ratio (ICR) of 1.88x raises concerns about the company’s ability to meet interest obligations comfortably, particularly as interest expenses increased to ₹17 Cr in March 2025. Additionally, the cash conversion cycle of 161 days indicates inefficiencies in managing working capital, as longer cycles can lead to liquidity issues.
Balance Sheet Strength and Financial Ratios
Evaluating Bal Pharma’s balance sheet reveals a mix of strengths and weaknesses. The company’s total borrowings amounted to ₹150 Cr, with reserves reported at ₹62 Cr, indicating a reliance on debt financing. The debt-to-equity ratio stood at a concerning 1.94x, suggesting that the company is heavily leveraged compared to industry norms, which typically hover around 1.0x for stable firms. The current ratio of 1.07x and quick ratio of 0.60x reflect a moderate liquidity position, with the quick ratio indicating potential short-term liquidity challenges. The book value per share, recorded at ₹48.63, provides a buffer against market fluctuations, although the price-to-book value (P/BV) ratio of 1.71x suggests that the stock is trading at a premium relative to its book value. Overall, while Bal Pharma maintains a reasonable level of assets, its high debt levels and liquidity ratios warrant close scrutiny.
Shareholding Pattern and Investor Confidence
The shareholding structure of Bal Pharma demonstrates a stable yet concentrated ownership. As of March 2025, promoters held 50.87% of the shares, reflecting a consistent commitment to the company. Foreign institutional investors (FIIs) accounted for a mere 0.23% of the shareholding, which is low compared to typical sector averages that often see higher foreign participation. The public ownership stood at 48.91%, indicating a relatively broad base of retail investors. The number of shareholders peaked at 16,466 in December 2022 but has since declined to 15,774 by March 2025, raising potential concerns about investor confidence. The limited presence of FIIs and the declining number of shareholders may indicate a lack of robust market perception regarding the company’s future prospects. This dynamic may affect the stock’s liquidity and market performance, particularly in challenging economic conditions.
Outlook, Risks, and Final Insight
Looking ahead, Bal Pharma faces several risks and opportunities. The decline in sales and profitability metrics suggests that the company must address operational inefficiencies to enhance its competitive position in the pharmaceuticals sector. Risks include high debt levels, which could strain cash flows during economic downturns, and the potential for further fluctuations in revenue that may impact investor sentiment. Conversely, strengths such as a solid promoter holding and a reasonable operating profit margin offer some stability. The ability to innovate and manage costs effectively will be crucial for Bal Pharma to navigate the challenging landscape ahead. If the company can improve its operational efficiency and manage its debt levels, there is potential for recovery and growth. However, failure to address these challenges may hinder its ability to attract new investors and sustain its market position.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bal Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 247/84.3 | 32.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,887 Cr. | 449 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.5 Cr. | 24.9 | 29.1/17.0 | 38.0 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,639.20 Cr | 1,185.06 | 56.65 | 197.01 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69.84 | 75.31 | 76.62 | 82.45 | 70.39 | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 |
| Expenses | 64.80 | 69.53 | 70.47 | 74.29 | 63.95 | 84.84 | 73.87 | 85.03 | 67.89 | 66.00 | 65.40 | 74.24 | 59.81 |
| Operating Profit | 5.04 | 5.78 | 6.15 | 8.16 | 6.44 | 7.70 | 7.79 | 9.60 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 |
| OPM % | 7.22% | 7.67% | 8.03% | 9.90% | 9.15% | 8.32% | 9.54% | 10.14% | 8.70% | 10.44% | 10.59% | 9.33% | 9.20% |
| Other Income | 0.24 | 0.05 | 0.46 | 0.19 | 0.16 | 0.14 | 0.10 | 2.45 | 0.82 | -0.20 | 0.51 | 1.08 | 0.72 |
| Interest | 2.37 | 2.86 | 3.11 | 3.85 | 3.64 | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 |
| Depreciation | 2.23 | 2.37 | 2.45 | 2.09 | 2.53 | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 |
| Profit before tax | 0.68 | 0.60 | 1.05 | 2.41 | 0.43 | 1.60 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 |
| Tax % | 58.82% | 78.33% | 43.81% | 32.78% | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0.00% |
| Net Profit | 0.28 | 0.12 | 0.59 | 1.62 | 0.09 | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 |
| EPS in Rs | 0.18 | 0.07 | 0.36 | 1.02 | 0.05 | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.30 | 3.41 | 0.13 |
Last Updated: August 20, 2025, 1:10 pm
Below is a detailed analysis of the quarterly data for Bal Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 65.87 Cr.. The value appears to be declining and may need further review. It has decreased from 81.88 Cr. (Mar 2025) to 65.87 Cr., marking a decrease of 16.01 Cr..
- For Expenses, as of Jun 2025, the value is 59.81 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 74.24 Cr. (Mar 2025) to 59.81 Cr., marking a decrease of 14.43 Cr..
- For Operating Profit, as of Jun 2025, the value is 6.06 Cr.. The value appears to be declining and may need further review. It has decreased from 7.64 Cr. (Mar 2025) to 6.06 Cr., marking a decrease of 1.58 Cr..
- For OPM %, as of Jun 2025, the value is 9.20%. The value appears to be declining and may need further review. It has decreased from 9.33% (Mar 2025) to 9.20%, marking a decrease of 0.13%.
- For Other Income, as of Jun 2025, the value is 0.72 Cr.. The value appears to be declining and may need further review. It has decreased from 1.08 Cr. (Mar 2025) to 0.72 Cr., marking a decrease of 0.36 Cr..
- For Interest, as of Jun 2025, the value is 4.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.95 Cr. (Mar 2025) to 4.05 Cr., marking an increase of 0.10 Cr..
- For Depreciation, as of Jun 2025, the value is 2.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.18 Cr. (Mar 2025) to 2.52 Cr., marking an increase of 0.34 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 2.59 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 2.38 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be increasing, which may not be favorable. It has increased from -108.88% (Mar 2025) to 0.00%, marking an increase of 108.88%.
- For Net Profit, as of Jun 2025, the value is 0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 5.41 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 5.20 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.13. The value appears to be declining and may need further review. It has decreased from 3.41 (Mar 2025) to 0.13, marking a decrease of 3.28.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:38 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 179 | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 295 |
| Expenses | 161 | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 265 |
| Operating Profit | 18 | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 29 |
| OPM % | 10% | 9% | 7% | 6% | 8% | 8% | 3% | 10% | 9% | 8% | 9% | 10% | 10% |
| Other Income | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 2 |
| Interest | 7 | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 |
| Depreciation | 5 | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 10 |
| Profit before tax | 7 | 5 | 3 | 3 | 3 | -0 | -14 | 4 | 9 | 5 | 9 | 5 | 5 |
| Tax % | 23% | 25% | 90% | 114% | 87% | -1,175% | -5% | -15% | 38% | 45% | 18% | -41% | |
| Net Profit | 5 | 4 | 1 | -0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 7 |
| EPS in Rs | 4.56 | 2.82 | 1.10 | 1.24 | 1.96 | 2.67 | -8.62 | 3.20 | 3.78 | 1.64 | 4.68 | 4.53 | 4.49 |
| Dividend Payout % | 22% | 35% | 91% | 81% | 51% | 37% | 0% | 31% | 26% | 61% | 26% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -20.00% | -75.00% | -100.00% | -750.00% | 138.46% | 20.00% | -50.00% | 133.33% | 0.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -55.00% | -25.00% | -650.00% | 888.46% | -118.46% | -70.00% | 183.33% | -133.33% |
Bal Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 12% |
| 3 Years: | 3% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 21% |
| 3 Years: | 13% |
| TTM: | -5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | -3% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 10% |
Last Updated: September 5, 2025, 12:20 am
Balance Sheet
Last Updated: October 10, 2025, 1:42 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 |
| Reserves | 39 | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 |
| Borrowings | 51 | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 |
| Other Liabilities | 54 | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 |
| Total Liabilities | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 |
| Fixed Assets | 55 | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 |
| CWIP | 0 | 1 | 4 | 2 | 0 | 4 | 3 | -0 | 2 | -0 | 0 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | 7 | 2 |
| Other Assets | 99 | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 |
| Total Assets | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 |
Below is a detailed analysis of the balance sheet data for Bal Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
- For Reserves, as of Mar 2025, the value is 62.00 Cr.. The value appears strong and on an upward trend. It has increased from 56.00 Cr. (Mar 2024) to 62.00 Cr., marking an increase of 6.00 Cr..
- For Borrowings, as of Mar 2025, the value is 150.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 140.00 Cr. (Mar 2024) to 150.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 108.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 108.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 336.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 320.00 Cr. (Mar 2024) to 336.00 Cr., marking an increase of 16.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 87.00 Cr.. The value appears strong and on an upward trend. It has increased from 80.00 Cr. (Mar 2024) to 87.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 3.00 Cr., marking an increase of 3.00 Cr..
- For Investments, as of Mar 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 5.00 Cr..
- For Other Assets, as of Mar 2025, the value is 244.00 Cr.. The value appears strong and on an upward trend. It has increased from 233.00 Cr. (Mar 2024) to 244.00 Cr., marking an increase of 11.00 Cr..
- For Total Assets, as of Mar 2025, the value is 336.00 Cr.. The value appears strong and on an upward trend. It has increased from 320.00 Cr. (Mar 2024) to 336.00 Cr., marking an increase of 16.00 Cr..
However, the Borrowings (150.00 Cr.) are higher than the Reserves (62.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -33.00 | -32.00 | -74.00 | -78.00 | -93.00 | -106.00 | -113.00 | -85.00 | -80.00 | -106.00 | -109.00 | -120.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 88 | 105 | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 |
| Inventory Days | 122 | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 |
| Days Payable | 129 | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 |
| Cash Conversion Cycle | 86 | 78 | 87 | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 |
| Working Capital Days | 11 | 14 | 50 | 26 | 45 | 25 | -11 | 11 | 18 | 13 | 12 | 6 |
| ROCE % | 11% | 7% | 8% | 8% | 7% | -0% | 10% | 12% | 10% | 12% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.54 | 4.94 | 1.67 | 3.79 | 3.34 |
| Diluted EPS (Rs.) | 4.54 | 4.96 | 1.68 | 3.79 | 3.34 |
| Cash EPS (Rs.) | 10.68 | 11.08 | 7.49 | 9.95 | 9.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.63 | 43.82 | 40.60 | 39.46 | 35.99 |
| Revenue From Operations / Share (Rs.) | 190.37 | 214.64 | 193.89 | 189.72 | 169.02 |
| PBDIT / Share (Rs.) | 19.95 | 21.75 | 16.61 | 19.31 | 17.27 |
| PBIT / Share (Rs.) | 13.81 | 15.38 | 10.79 | 13.21 | 10.85 |
| PBT / Share (Rs.) | 3.23 | 5.72 | 3.03 | 6.20 | 2.77 |
| Net Profit / Share (Rs.) | 4.54 | 4.71 | 1.67 | 3.85 | 3.18 |
| NP After MI And SOA / Share (Rs.) | 4.53 | 4.68 | 1.64 | 3.79 | 3.20 |
| PBDIT Margin (%) | 10.47 | 10.13 | 8.56 | 10.18 | 10.21 |
| PBIT Margin (%) | 7.25 | 7.16 | 5.56 | 6.96 | 6.41 |
| PBT Margin (%) | 1.69 | 2.66 | 1.56 | 3.26 | 1.63 |
| Net Profit Margin (%) | 2.38 | 2.19 | 0.86 | 2.02 | 1.88 |
| NP After MI And SOA Margin (%) | 2.38 | 2.17 | 0.84 | 1.99 | 1.89 |
| Return on Networth / Equity (%) | 9.32 | 10.66 | 4.03 | 9.57 | 8.85 |
| Return on Capital Employeed (%) | 18.92 | 20.86 | 16.30 | 20.64 | 18.36 |
| Return On Assets (%) | 2.14 | 2.31 | 0.82 | 2.15 | 1.97 |
| Long Term Debt / Equity (X) | 0.40 | 0.52 | 0.47 | 0.46 | 0.44 |
| Total Debt / Equity (X) | 1.94 | 2.01 | 2.05 | 1.67 | 1.95 |
| Asset Turnover Ratio (%) | 0.92 | 1.07 | 1.06 | 1.12 | 0.99 |
| Current Ratio (X) | 1.07 | 1.15 | 1.09 | 1.11 | 1.08 |
| Quick Ratio (X) | 0.60 | 0.72 | 0.62 | 0.66 | 0.68 |
| Inventory Turnover Ratio (X) | 3.18 | 1.95 | 2.08 | 2.43 | 2.12 |
| Dividend Payout Ratio (NP) (%) | 26.47 | 21.22 | 60.55 | 26.41 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 11.24 | 8.98 | 13.30 | 10.11 | 0.00 |
| Earning Retention Ratio (%) | 73.53 | 78.78 | 39.45 | 73.59 | 0.00 |
| Cash Earning Retention Ratio (%) | 88.76 | 91.02 | 86.70 | 89.89 | 0.00 |
| Interest Coverage Ratio (X) | 1.88 | 2.25 | 2.14 | 2.75 | 2.14 |
| Interest Coverage Ratio (Post Tax) (X) | 1.43 | 1.49 | 1.21 | 1.55 | 1.39 |
| Enterprise Value (Cr.) | 274.72 | 270.49 | 228.31 | 252.09 | 180.34 |
| EV / Net Operating Revenue (X) | 0.90 | 0.79 | 0.75 | 0.89 | 0.71 |
| EV / EBITDA (X) | 8.65 | 7.87 | 8.76 | 8.81 | 7.05 |
| MarketCap / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| Retention Ratios (%) | 73.52 | 78.77 | 39.44 | 73.58 | 0.00 |
| Price / BV (X) | 1.71 | 2.08 | 1.65 | 2.73 | 1.49 |
| Price / Net Operating Revenue (X) | 0.43 | 0.42 | 0.34 | 0.56 | 0.31 |
| EarningsYield | 0.05 | 0.05 | 0.02 | 0.03 | 0.05 |
After reviewing the key financial ratios for Bal Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.94 (Mar 24) to 4.54, marking a decrease of 0.40.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 5. It has decreased from 4.96 (Mar 24) to 4.54, marking a decrease of 0.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.68. This value is within the healthy range. It has decreased from 11.08 (Mar 24) to 10.68, marking a decrease of 0.40.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.63. It has increased from 43.82 (Mar 24) to 48.63, marking an increase of 4.81.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 190.37. It has decreased from 214.64 (Mar 24) to 190.37, marking a decrease of 24.27.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 19.95. This value is within the healthy range. It has decreased from 21.75 (Mar 24) to 19.95, marking a decrease of 1.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.81. This value is within the healthy range. It has decreased from 15.38 (Mar 24) to 13.81, marking a decrease of 1.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.23. This value is within the healthy range. It has decreased from 5.72 (Mar 24) to 3.23, marking a decrease of 2.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.54. This value is within the healthy range. It has decreased from 4.71 (Mar 24) to 4.54, marking a decrease of 0.17.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.53. This value is within the healthy range. It has decreased from 4.68 (Mar 24) to 4.53, marking a decrease of 0.15.
- For PBDIT Margin (%), as of Mar 25, the value is 10.47. This value is within the healthy range. It has increased from 10.13 (Mar 24) to 10.47, marking an increase of 0.34.
- For PBIT Margin (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 7.16 (Mar 24) to 7.25, marking an increase of 0.09.
- For PBT Margin (%), as of Mar 25, the value is 1.69. This value is below the healthy minimum of 10. It has decreased from 2.66 (Mar 24) to 1.69, marking a decrease of 0.97.
- For Net Profit Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 5. It has increased from 2.19 (Mar 24) to 2.38, marking an increase of 0.19.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 8. It has increased from 2.17 (Mar 24) to 2.38, marking an increase of 0.21.
- For Return on Networth / Equity (%), as of Mar 25, the value is 9.32. This value is below the healthy minimum of 15. It has decreased from 10.66 (Mar 24) to 9.32, marking a decrease of 1.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.92. This value is within the healthy range. It has decreased from 20.86 (Mar 24) to 18.92, marking a decrease of 1.94.
- For Return On Assets (%), as of Mar 25, the value is 2.14. This value is below the healthy minimum of 5. It has decreased from 2.31 (Mar 24) to 2.14, marking a decrease of 0.17.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.40. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.40, marking a decrease of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.94. This value exceeds the healthy maximum of 1. It has decreased from 2.01 (Mar 24) to 1.94, marking a decrease of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.92. It has decreased from 1.07 (Mar 24) to 0.92, marking a decrease of 0.15.
- For Current Ratio (X), as of Mar 25, the value is 1.07. This value is below the healthy minimum of 1.5. It has decreased from 1.15 (Mar 24) to 1.07, marking a decrease of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.60. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.60, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.18. This value is below the healthy minimum of 4. It has increased from 1.95 (Mar 24) to 3.18, marking an increase of 1.23.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 26.47. This value is within the healthy range. It has increased from 21.22 (Mar 24) to 26.47, marking an increase of 5.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.24. This value is below the healthy minimum of 20. It has increased from 8.98 (Mar 24) to 11.24, marking an increase of 2.26.
- For Earning Retention Ratio (%), as of Mar 25, the value is 73.53. This value exceeds the healthy maximum of 70. It has decreased from 78.78 (Mar 24) to 73.53, marking a decrease of 5.25.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.76. This value exceeds the healthy maximum of 70. It has decreased from 91.02 (Mar 24) to 88.76, marking a decrease of 2.26.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.88. This value is below the healthy minimum of 3. It has decreased from 2.25 (Mar 24) to 1.88, marking a decrease of 0.37.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 3. It has decreased from 1.49 (Mar 24) to 1.43, marking a decrease of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 274.72. It has increased from 270.49 (Mar 24) to 274.72, marking an increase of 4.23.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.79 (Mar 24) to 0.90, marking an increase of 0.11.
- For EV / EBITDA (X), as of Mar 25, the value is 8.65. This value is within the healthy range. It has increased from 7.87 (Mar 24) to 8.65, marking an increase of 0.78.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For Retention Ratios (%), as of Mar 25, the value is 73.52. This value exceeds the healthy maximum of 70. It has decreased from 78.77 (Mar 24) to 73.52, marking a decrease of 5.25.
- For Price / BV (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.71, marking a decrease of 0.37.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has increased from 0.42 (Mar 24) to 0.43, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bal Pharma Ltd:
- Net Profit Margin: 2.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.92% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 9.32% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.6
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.8 (Industry average Stock P/E: 56.65)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.94
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | # 21 & 22, Bengaluru Karnataka 560099 | info@balpharma.com http://www.balpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Ravindrakumar Kothari | Non Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Independent Director |
FAQ
What is the intrinsic value of Bal Pharma Ltd?
Bal Pharma Ltd's intrinsic value (as of 07 November 2025) is 67.85 which is 15.61% lower the current market price of 80.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 128 Cr. market cap, FY2025-2026 high/low of 141/76.3, reserves of ₹62 Cr, and liabilities of 336 Cr.
What is the Market Cap of Bal Pharma Ltd?
The Market Cap of Bal Pharma Ltd is 128 Cr..
What is the current Stock Price of Bal Pharma Ltd as on 07 November 2025?
The current stock price of Bal Pharma Ltd as on 07 November 2025 is 80.4.
What is the High / Low of Bal Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bal Pharma Ltd stocks is 141/76.3.
What is the Stock P/E of Bal Pharma Ltd?
The Stock P/E of Bal Pharma Ltd is 17.8.
What is the Book Value of Bal Pharma Ltd?
The Book Value of Bal Pharma Ltd is 48.6.
What is the Dividend Yield of Bal Pharma Ltd?
The Dividend Yield of Bal Pharma Ltd is 1.49 %.
What is the ROCE of Bal Pharma Ltd?
The ROCE of Bal Pharma Ltd is 10.1 %.
What is the ROE of Bal Pharma Ltd?
The ROE of Bal Pharma Ltd is 9.66 %.
What is the Face Value of Bal Pharma Ltd?
The Face Value of Bal Pharma Ltd is 10.0.